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Abstract
Non-communicable diseases (NCDs) were previously considered to only affect high-income countries. However,
they now account for a very large burden in terms of both mortality and morbidity in low- and middle-income
countries (LMICs), although little is known about the impact these diseases have on households in these countries.
In this paper, we present a literature review on the costs imposed by NCDs on households in LMICs. We examine
both the costs of obtaining medical care and the costs associated with being unable to work, while discussing the
methodological issues of particular studies. The results suggest that NCDs pose a heavy financial burden on many
affected households; poor households are the most financially affected when they seek care. Medicines are usually
the largest component of costs and the use of originator brand medicines leads to higher than necessary expenses.
In particular, in the treatment of diabetes, insulin – when required – represents an important source of spending for
patients and their families. These financial costs deter many people suffering from NCDs from seeking the care they
need. The limited health insurance coverage for NCDs is reflected in the low proportions of patients claiming
reimbursement and the low reimbursement rates in existing insurance schemes. The costs associated with lost
income-earning opportunities are also significant for many households. Therefore, NCDs impose a substantial
financial burden on many households, including the poor in low-income countries. The financial costs of obtaining
care also impose insurmountable barriers to access for some people, which illustrates the urgency of improving
financial risk protection in health in LMIC settings and ensuring that NCDs are taken into account in these systems.
In this paper, we identify areas where further research is needed to have a better view of the costs incurred by
households because of NCDs; namely, the extension of the geographical scope, the inclusion of certain diseases
hitherto little studied, the introduction of a time dimension, and more comparisons with acute illnesses.
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Background
The 2010 WHO Global Status report on non-commu-
nicable diseases (NCDs) showed that they are now the
most important cause of mortality worldwide. Indeed,
more than 36 million people died from NCDs in 2008,
mainly cardiovascular diseases (48%), cancers (21%),
chronic respiratory diseases (12%), and diabetes (3%).
Nearly 80% of these deaths occurred in low- and middle-
income countries (LMICs), where, on average, they now
exceed communicable diseases as the major cause of dis-
ease burden [1]. Even in the remaining countries where
infectious diseases are the main health problem, NCDs
are growing rapidly. NCDs are expected to exceed com-
municable, puerperal, prenatal and food diseases on the
list of leading causes of death in all countries by
2020. The increasing importance of NCDs has caused
them to no longer be viewed simply as a health issue
but rather as a development issue worthy of discus-
sion at a High-level Meeting of the 66th General As-
sembly of United Nations [2].
Considerable literature exists on the impact of NCDs
on households in high-income countries [3-7]; resear-
chers are now beginning to examine the implications of
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NCDs in low- and middle-income settings as well [8].
Indeed, the impact is expected to differ because there is
little financial risk protection in many LMICs and thus
financial costs are largely borne by households them-
selves rather than governments or insurance schemes
[9]. The framework presented in Figure 1 describes the
channels through which NCDs can affect the economic
welfare of households.
We conducted a literature review to present existing
evidence on the financial burden from NCDs in low-
and middle-income settings, at the individual and house-
hold level. The aim is to provide accurate and relevant
information on this important issue to policymakers,
and determine where further research is needed.
Methods
We performed a literature search with Cabdirect, Scien-
cedirect and Web of Knowledge, using combinations of
the following key words: “Non-communicable disease”,
“chronic illness”, “diabetes”, “cardiovascular disease”,
“cancer”, and “chronic respiratory disease” with “cost”,
“impoverish”, “financial burden”, “health expenditure”,
“expense”, “out-of-pocket”, “health spending”, “catastro-
phic expenditure”, “catastrophic expense”, and “catas-
trophic spending”. A total of 8,966 results (including
duplicates) were obtained. After duplicate removal, titles
and abstracts of the remaining papers were reviewed to
assess their relevance according to the following inclu-
sion criteria: i) papers in English or French; ii) from
1990 onwards; iii) covering at least one low-, lower-
middle- or upper-middle-income countrya [11]; iv)
measuring the household or individual financial costs; v)
of one condition (or more) falling under the definition
of “chronic diseases” [12] or classified in “Group II dis-
eases” according to the ICD-10 code [8]. This screening
led to the selection 43 articles and a secondary literature
Illness 
experience
Treatment 
seeking 
behaviour
Economic 
consequences
Coping strategies & 
social resources
Reduced well-
being and 
increased financial 
vulnerability for 
individuals & 
households
Intra- & inter-
household labour 
substitution
Hiring other labour 
& other strategies
Use of savings
Reducing/delaying 
consumption of non-
health goods & 
services (food, 
education, electricity,
leisure, etc.)
Sale of assets
Borrowing
Delaying 
investments
Other strategies to 
cope with financial 
costs (assistance 
from others, etc.)
Non-
communica
ble disease
Indirect 
costs
Seek 
care
No
Yes
Directs 
costs
Loss of working time
of person who is ill & 
caregivers
Loss of income of 
person who is ill & 
caregivers (due to 
absenteeism, missing 
business 
appointments, etc.)
Financial costs of 
health care 
(consultation, 
medicines, laboratory, 
hospitalization, etc.)
Other financial costs
related to seeking 
care (transportation, 
special dietary 
regimes, etc.)
Figure 1 Framework for the analysis of economic impacts of NCDs on households (modified from McIntyre et al. [10]).
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search was performed using the references cited in these
selected papers. Finally, a total of 49 papers were identi-
fied, whose full-length versions were obtained for this re-
view. Each of these studies was examined for information
on disease(s), study population, analysis methods and
findings. These details are presented in Additional file 1:
Table S1.
Results
Overview of the methods used in the literature
The studies found in the literature reflect the diversity of
methods used to assess household financial burden from
NCDs. The methodological differences in the studies in-
herently prevent a formal meta-analysis from being
performed. However, at the same time, these differences
offer opportunities to explore results through the lens of
different techniques. In this section, we present a discus-
sion on the methodologies used.
Some studies look at a specific NCD (e.g., diabetes,
cancers, cardiovascular diseases), while a majority con-
sider NCDs in general or a combination of two or more
specific NCDs. We found only one previous literature
review which included studies on multiple NCDs, but it
includes studies from only a few countries and did not
include any studies from Africa and Latin America [13].
The original studies found also differed according to
data sources and sample sizes. Some authors conducted
their own surveys for the purpose of the studies, while
others used data from existing surveys carried out by an-
other entity (e.g., National Institute of Statistics, Ministry
of Health, Health Insurance Plans). In these surveys,
households and individuals were generally chosen ran-
domly, through simple, stratified or cluster sampling
[14-22]. However, many studies used convenient samples
of patients suffering from a specific illness in health care
facilities, something that we report when presenting the
results [23-31]. Additionally, studies looking at specific
diseases generally used relatively small samples, while
those considering a broad set of diseases usually relied
on bigger samples. For the assessment of diabetes costs,
for example, some studies selected a small number of
diabetic patients: 50 in North India, 53 in Cape Town
(South Africa) and 77 in Ghana [23,25,32]. Similarly, in a
study in Enugu (Nigeria), Obi and Ozumba used a sam-
ple of 95 patients suffering from cervical cancer [27]. On
the other hand, up to 206,700 individuals from 48,600
households were included in a study on chronic diseases
in Mexico [33]. In terms of internal validity of findings,
some studies used hospital registries or insurance reim-
bursement records to verify the information reported by
patients and/or their relatives during face-to-face in-
terviews [34-36]; a majority of studies, however, sim-
ply accepted the answers of the respondents as being
valid. Finally, some studies use data from focus group
discussions and key informant interviews to comple-
ment their analyses [18,32,37-39].
In the studies looking at NCDs in general, the term
“chronic diseases” is frequently used, and even if the
major NCDs are usually taken into account, the defini-
tions vary from one study to another. For example, Shi
et al. defined a chronic ailment as an ailment that lasts
or is expected to last for at least 12 months, resulting in
functional limitations or the need for ongoing medical
services, and includes disability [15]. In Kenya, Chuma
et al. defined chronic illnesses as those reported to have
lasted three months or more [38], while for Goudge
et al., any illness that had persisted for longer than a
month was defined as chronic [37]. Mondal et al. con-
sidered that a chronic illness is a condition that lasts
more than three weeks, which needs to be managed on
a long-term basis [40]. However, many of these studies
provide the list of diseases they considered as chronic,
and thus it was possible to know whether NCDs were
included along with some communicable diseases (for
example, HIV/AIDS). In these cases, we report results
related only to chronic NCDs. Nevertheless, in some
studies it was not possible to be sure that the focus was
limited to only chronic NCDs.
Irrespective of the diseases considered, many studies
assessing the direct costs incurred by households for the
treatment of NCDs also focus on impoverishment and
catastrophic health expenditure due to these expenses.
Impoverishment occurs when a respondent would have
had a net income above the poverty line in the absence
of the expenditure on the disease, but below it after. Dif-
ferent poverty lines are used across studies – US$ 1 per
day, US$ 1.08 per day, US$ 1.25 per day and US$ 2 per
day [28,35,39,41,42].
Catastrophic heath expenditure occurs when people
spend a disproportionate amount of their income (some-
times non-food expenditure) on the condition, as de-
scribed in Xu et al. [43]. However, a great variety of
specific definitions for catastrophic health expenditure
were used in the studies presented here. The thresholds
for determining a disproportionate level of expenditure
vary from 10% to 60%; some studies deviated from this
more standard approach. For example, Mukherjee et al.
used the concept of “high health care expenditure” in-
stead of catastrophic health payments [44]. In this study,
a household was identified as having incurred high out-
of-pocket expenditure on health care if its annual health
care expenditure was high in comparison to those of other
households within the same caste group in India [44].
The evidence on the direct costs from non-communicable
illnesses
Many of the studies assessed direct costs, which include
all costs incurred by individuals and households for the
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treatment of NCDs. In theory, these costs should be net
of any reimbursement from insurance. We present evi-
dence on these direct costs organized by disease.
Diabetes
Diabetes is a leading NCD and 16 studies included in
this review looked at the direct costs incurred for both
outpatient and inpatient services. All studies, except
one, relied on convenience samples, so the results need
to be interpreted carefully. Overall, the studies found
that varying shares of household income are allocated to
paying for diabetes care. This ranges from as low as 5%
of income for a rural low-income population in India to
up to 24.5% for a low-income group in Madras (India)
[34,36,45]. Spending can also differ between richer and
poorer households and studies found that poorer house-
holds spend a higher proportion of their income on care
for diabetes than richer households. These differences
can be quite striking – one study from India found that
in urban areas, the share of income spent on diabetes
care in the poorest households was seven times that of
the richest households [45]. Spending on diabetes can
also be a considerable share of overall household health
spending. A study in Sudan reported that on average
65% of household health expenditure was spent on ca-
ring for a child with diabetes [46].
Medications are frequently found to be the largest
component of expenditure on diabetes [47]. Spending
on medications represented from 32% to 62% of total ex-
penditure on diabetes care in various setting such as
India, Mexico, Pakistan and Sudan (Table 1). In rural
Ghana, spending on insulin alone represents around
60% of the monthly income of those on the minimum
daily wage [32]. Using originator-brand medication re-
sulted in much higher spending in the only diabetes
study that used random sampling rather than conveni-
ence samples. This study found that in Yemen and Mali,
purchasing an originator brand medicine for gliben-
clamide (a medicine used to treat type II diabetes) in the
private sector was found to potentially impoverish an
additional 22% and 29% of the population, respectively,
versus 3% and 19%, respectively, if the lowest priced
generic product was purchased [41]. Laboratory and
transportation costs were generally the second largest
component of expenditure. Some studies also document
expenditure related to special dietary regimes (up to 20%
of the direct costs in North India [23]).
The presence of complications and the duration of the
illness are usually associated with an increase of the dir-
ect costs. For example, Khowaja et al. found that in
Pakistan, the direct cost for patients with co-morbidities
was 45% higher than the direct cost for patients without
co-morbidities [50]. Similarly, in India, those without
complications were found to have an 18% lower cost
compared to the mean annual cost for outpatient care
for all patients with diabetes, while those with three
or more complications had a 48% higher cost [51].
Similar results were found in India, China, Thailand
and Malaysia [34,36,45,48]. These studies also high-
light the fact that treatment at an early stage is much
cheaper for households than treatment at a later stage
with complications.
Some studies looked at coping strategies used by
households to pay for these direct costs. In India, the
majority of patients (89%) used their household income
to fund the monitoring and treatment of their diabetes,
while household savings were used by 22% of retired pa-
tients and by 19% of those in the lowest income bracket.
When faced with hospitalization, 56% of patients had to
dip into their savings or borrow in order to fund the
costs [51]. Additionally, very few households are reim-
bursed by insurance. In India, Kapur found that only 1%
of patients claimed the costs of treatment on insurance
[51], while Ramachandran et al. observed that medical
reimbursement was obtained by 14.2% of urban pa-
tients but by only 3.2% of rural patients [45]. More-
over, Khowaja et al. found that in Pakistan, none of the
persons with diabetes indicated that their cost was borne
by an insurance company or their employer [50].
Cardiovascular diseases
Five studies examined spending on cardiovascular dis-
eases. In a study using data from a household survey in
Kazakhstan, people with cardiac problems were found to
pay on average 24% more for health care than people
with other health problems [22]. As with diabetes, stud-
ies from Congo and Uganda also found that the use of
originator brand drugs increases spending on cardiovas-
cular diseases [24,41]. Once again, there was only one
cardiovascular disease study that did not use a conveni-
ence sample [41].
Out-of-pocket payments for the treatment of cardio-
vascular diseases also lead to significant costs for house-
holds. Up to 71% of patients who had experienced
an acute stroke were found to face catastrophic health
Table 1 Shares of diabetes expenditure spent on
medications
Authors* Countries Spending on medicines
as a percentage of
total expenditure on
diabetes (%)
Rayappa et al. [48] India 32
Elrayah et al. [46] Sudan 36 (only insulin)
Villarreal-Ríos et al. [49] Mexico 37
Khowaja et al. [50] Pakistan 46
Grover et al. [23] India 62
*All these papers are based on convenience samples.
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expenditureb in China, while 37% of them fell below the
poverty line of US$ 1 per day after paying for their
health care [35]. The study of Heeley et al. also found
that catastrophic payments and impoverishment due to
cardiovascular diseases are more common in people
with no health insurance than in those with health insu-
rance [35].
In a study covering 35 states and union territories in
India, Rao et al. investigated the coping strategies used
by households to deal with expenses incurred for hospi-
talizations due to cardiovascular diseases [52]; 57% of
these expenses were paid from household savings, 35%
from borrowings, and 8% from the sale of assets. In the
poorest group, up to 55% of out-of-pocket spending was
financed through borrowings, and only 38% through
savings [52].
Cancer
Cancers also represent an emerging health problem in
LMICs and seeking health care for these diseases can
have a significant effect on families’ welfare. We found
three papers which focus specifically on the direct cost
from cancers. In a study using data from a randomized
household survey in Pakistan, 27.1% of those who sought
care for cancer at private facilities were found to finance
their care through unsecured loans, while 7.1% relied on
assistance from others [53].
Two studies using convenience samples also shed
some light on components of spending on cancer care.
Indeed, Zhou et al. found that health insurance facili-
tates the financial access of treatment for patients suffer-
ing from oesophageal cancer in China, particularly for
purchasing drugs [31]. Meanwhile, transportation, mul-
tiple investigations, radiotherapy and chemotherapy
were the main components of direct costs for cervical
cancer in Nigeria [27].
Other non-communicable diseases
The financial burden from other NCDs, such as epi-
lepsy, cirrhosis, chronic obstructive pulmonary disease
(COPD), rhinitis and depressive disorders, is also esti-
mated in some studies. Even if they are not as studied
as the major NCDs presented previously, these types of
illnesses can also exert a considerable pressure on
household finances. For example, a study from Mumbai
(India) based on a random sample of households found
that the share of the annual personal income spent on
outpatient care for allergic rhinitis was 1.7% when treat-
ment was sought in public facilities. Similarly, care for
COPD represented 13.3% of annual personal income
among those using private facilities. With hospitalization
at public facilities, out-of-pocket payments for COPD
represented up to 62.3% of the annual personal income
compared to 50.7% for hospitalization in private facilities
[54]. Using a focus group, Russell and Gilson document
the case of an individual suffering from asthma, who in-
curred a direct cost representing 15% of his monthly
wage when seeking care for a sore chest in a private
clinic and pharmacy [39]. Multiple laboratory tests and
the presence of complications were also found to cause
high expenses for a convenience sample of patients suf-
fering from cirrhosis in Brazzaville (Congo) [26].
Coping strategies used to pay for care associated with
these NCDs are similar to those used to cope with more
documented NCDs. In Pakistan for example, Mahmood
and Ali Mubashir using a random sample found that
22.9% of patients with circulatory diseases (heart dis-
eases, rheumatic fever and blood pressure) who visited
private doctors/clinics for treatment financed care
through unsecured loans, while 8.8% relied on assistance
from others [53]. Among those who did not visit any fa-
cility, 67.4% reported financial constraints as the reason
for not seeking care.
Non-communicable diseases combined
We found a large number of studies – all based on ran-
domized household surveys – looking at NCDs in gen-
eral, instead of focusing on specific illnesses. Some
studies highlight the association of having a household
member suffering from a chronic disease with a signifi-
cant increase in health care expenditure and a higher
risk of impoverishment. In Russia, for example, each
additional case of chronic disease in a household was
found to increase the probability of incurring health care
expenditure by 8% and the amount of healthcare ex-
penditure by 6.2% [19]. Similarly, in Uganda, households
with a member suffering from a chronic illness were
found to be three times more likely to incur costs for
health care than other households [18]. In Kazakhstan,
people with chronic illness were found to pay on average
18% more than people with other health problems, while
in Georgia, the mean cost for outpatient care in case of
chronic illness was almost two times higher than in case
of acute illness [21,22]. On the other hand, a study from
India found that the relative importance of chronic dis-
eases for spending may be lower – the mean annual per
capita health expenditure for a chronic episode was 11%
lower than for an acute one [44].
Undeniably, expenses incurred when seeking health
care for chronic diseases represent an important finan-
cial burden for households as presented in Table 2. In
fact, the costs of health care for chronic illnesses were
found to represent from 5.0% of household income in
rural Kenya to up to 30–50% of monthly income for vul-
nerable households in South Africa, where care for these
illnesses were unaffordable without gifts from social net-
works [37,38]. Similarly, household spending on chronic
illness represented 4.14% of household’s total annual
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health care expenditure in urban areas and 5.73% in
rural areas of West Bengal in India; however, it was up
to 11% in Vietnam and 32% in Maharashtra, Bihar and
Tamil Nadu states of India, with a higher share for
hospitalization and drugs [20,40,55]. All these studies
used a random sample. Another proxy of households’
capacity to pay used in the literature is their non-food
expenditure. Sun et al. found that in China, the average
proportion of chronic disease expenditure to annual
non-food expenditure was about 27% in Shandong
Province and 35% in Ningxia province for patients
covered by New Cooperative Medical Scheme (NCMS), a
public health insurance scheme for rural residents [16].
For non-NCMS members, these proportions were 47%
and 42%, respectively.
In several studies, the presence of household members
with chronic ailments was also found to lead to cata-
strophic health expenditure and impoverishment. The
probability of catastrophic expenditure was then 4.4
times higher among households having incurred ex-
penses for treating chronically ill persons in Georgia,
and up to 7.8 times higher in Burkina-Faso [17,56]. Si-
milar results were found in West Bengal (India), in
Lebanon and in China [15,40,57,58]. Up to 11.6% of
households in Western and Central China were pushed
under the US$ 1.08 poverty line after incurring out-
patient expenses associated with chronic diseases [42].
Moreover, Shi et al. found the incidence of medical im-
poverishment to reach 19.6% in households where more
than 50% of members had a chronic illness [16].
As with diabetes, when households are covered by
health insurance, the reimbursement rates for chronic
diseases are relatively low. In Shandong and Ningxia in
China, for example, only 11.16% and 8.67%, respectively,
of overall medical expenditure for chronic diseases was
reimbursed by the NCMS [16]. However, another study
from Western China found that health insurance pro-
vided protection against impoverishment due to ex-
penses for chronic diseases [42]. Government subsidies
for medicines were also found to lower the expenses for
many chronic diseases in Vietnam [29].
Coping strategies documented in the literature com-
bining chronic diseases are similar to those described in
the studies on specific NCDs. In Georgia, when house-
holds were lacking financial means, the most dominant
strategy was to borrow from a friend or relative (70%),
followed by selling household valuables (10%) and/or
household goods/products (10%) [21].
Literature on the indirect costs due to non-communicable
diseases in low- and middle-income countries
Households and individuals also bear indirect costs
when they are affected by NCDs. These costs mainly in-
clude time and productivity loss by patients and care-
givers because of the illness as well as income lost by
patients and family members. Whereas there is no doubt
that these indirect costs can pose a substantial burden
on households, there are numerous methodological chal-
lenges in measuring this burden adequately; these chal-
lenges have been discussed in detail in a previous study
Table 2 Expenditure on chronic diseases
Authors# Countries Spending on chronic
illnesses as a percentage
of household income (%)
Spending on chronic
illnesses as a percentage
of household total health
expenditure (%)
Spending on chronic
illnesses as a percentage
of household non-food
expenditure (%)
Chuma et al. [38] Kenya (rural) Urban: 5.7
Rural: 5
Goudge et al. [37] South Africa (Vulnerable households) 30–50
Mondal et al. [40] India (West Bengal) Urban: 4.14
Rural: 5.73
Thuan et al. [20] Vietnam 27.7* (curative)
11.1**
58.6***
Dror et al. [55] India (Maharashtra, Bihar and
Tamil Nadu states )
32
Sun et al. [16] China (Shandong province) NCMS: 27
Non-NCMS: 47
Sun et al. [16] China (Ningxia province) NCMS: 35
Non-NCMS: 42
#All these studies used randomized samples. *For all households. **For households which had catastrophic health care expenditure. ***For households having
health expenditure between 30% and 40% of their capacity to pay.
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[59]. Nonetheless, in this section, we present the avail-
able evidence on the indirect costs of NCDs as reported
in the literature. This constitutes findings from 11 stu-
dies, which mainly use convenience samples, on loss of
income, loss of time and other forms of financial loss re-
lated to these illnesses. We discuss possible limitations
of these findings in the discussion section.
Loss of income
In India, one study suggests that the indirect cost for
diabetes patients and their caregivers was 28.76% of the
total treatment cost. It was claimed that loss of income
of the patient comprised the greatest portion of indirect
costs (60.54%), followed by loss of income of caregivers
(39.46%) [23]. Rayappa et al. found that in Bangalore
(India), 30.9% of respondents suffering from diabetes
reported a change in personal income, and on average,
they faced a reduction of 20.9% of their personal income
[48]. In addition, 20.8% of the respondents reported
a change in family income, with a mean reduction of
17.4%. Similarly, Arrossi et al. found that in Argentina,
39% of households with a member suffering from cer-
vical cancer lost family income, partially or totally [28].
Among households that lost income, 47% lost less than
25% of family income, 34% lost 25–50% and 19% lost
50% or more of their income. As a result of the reported
loss of income, it was estimated that the proportion of
patient’s households living in poverty increased from
45% to 53%. Likewise, Obi and Ozumba found that in
Nigeria, all patients suffering from cervical cancer and
their relatives lost income from workplaces due to absen-
teeism, disengagement from work and missing business
appointments [27]. In a study covering 19 countries, one
of the two studies using randomized household survey
data documenting indirect costs, Levinson et al. found
that serious mental illness was associated with a potential
reduction in earnings of 10.9% of average national earn-
ings in LMICs [60]. The second study using randomized
household survey data was from Russia and found that
labour income decreased by 4.8% per additional case of
chronic disease in the household [19]. Some studies only
estimate the NCDs-related indirect costs for patients and
their families in absolute value (local currencies or US$)
[50,51,61].
Loss of working time
The loss of income borne by patients suffering from
NCDs is mainly due to self-reported absenteeism from
usual economic activity. In fact, the treatment of NCDs
usually requires repetitive visits to health facilities in
addition to the inability to work due to their poor health.
This can lead to additional losses of working time both
for patients and caregivers. In the literature, the mean
loss of working time reported by patients was found to
vary from 2.8 ± 1.7 hours per visit for diabetes in
Pakistan to 58 ± 105 days per year for epilepsy in India
[30,50]. Episodes of respiratory diseases can also cause
important losses of working time as shown in a case
study in Colombo (Sri Lanka) where Russell and Gilson
found a patient suffering from asthma took two days
off work for a sore chest, losing 6% of his monthly
wage [39].
However, time costs are not limited to patients, but
also affect caregivers. In Buenos Aires (Argentina) for
example, Arrossi et al. found that in 45% of households
with a member suffering from cervical cancer, at least
one member reduced his/her working hours [28]. For
diabetes patients in Thailand, caregivers were found to
spend on average 42.21 ±39.94 hours per month on health
care activities – e.g., giving medicines – and 21.87 ± 31.81
hours on activities of daily living – e.g., helping with eating
and dressing [61].
Other forms of indirect costs
Some other forms of indirect costs due to NCDs were
found in the literature; these generally concern house-
holds’ livelihood and welfare. The study on cervical
cancer in Buenos Aires (Argentina) by Arrossi et al. exa-
mined these and also found that due to a loss of income,
there were delays in payments for essential services such
as telephone or electricity and as a result 43% of house-
holds had the service cut [28].
There were also significant effects on self-reported
daily food consumption, which was reduced in 37% of
households, while 38% of households reported that they
sold property or used savings to offset income loss.
Some impacts on education were found and school ab-
sences were more prevalent in 28% of households. There
were also problems to pay for education in 23% of
households. Furthermore, 45% of patients were cared for
by one or more informal caregivers that did not live with
them and one-third of these caregivers’ households re-
duced their daily consumption of food and 26% had de-
lays in payments of essential services such as electricity
or telephone services. It should be noted that these are
the types of welfare losses have shaped the concept of
catastrophic health expenditure.
There were also direct impacts on employment and at
least one member stopped working in 28% of house-
holds affected by cervical cancer. Several interviewees
who stopped working expressed the hope of going back
to their jobs after treatment, fearing at the same time
that this would no longer be possible. Similarly, a study
from Bangalore (India) by Rayappa et al. found that only
33.4% of diabetes patients worked and among those
working, 23% experienced problems at their job, affec-
ting their productivity and at times requiring changing
work to a less strenuous job (5.9%) or giving up the job
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(14.7%) [48]. Considering NCDs in general, Abegunde
and Stanciole found that in Russia, chronic illnesses,
which included NCDs, impose a reduction of 5% in
household consumption of non-health-related items
[19].
Discussion
This literature review has presented the available evi-
dence on the household financial burden related to
NCDs in LMICs. However, before discussing its most
important results, it is important to highlight some of
the methodological issues in many of the studies that
were included. First, the heavy reliance on convenience
samples taken from people who are seeking and
obtaining treatment, often at hospitals, will almost cer-
tainly result in an upward bias in costs for the average
person with the condition. The people who do not seek
treatment or who seek treatment at a lower level of care,
implying lower costs, have no chance of being selected.
Second, self-reported costs, even from random sam-
ples of patients, are likely to be biased upwards when
there are no controls. Some of the people with the con-
dition would have incurred some health expenses in any
case and this can only be captured by including controls
without the condition [59,62]. In other words, it is likely
that part of the costs reported by patients with NCDs
were not directly associated with those conditions.
This issue is particularly important when considering
indirect costs. It is clear that the method of asking
people how many days they could not work overesti-
mates the true loss in work time from a disease because
many of the people, particularly in low-income coun-
tries, would not have been working on those days, or for
all of those days, in the absence of the disease [59]. Nor
do the studies consider whether absent workers are re-
placed by other family members in family enterprises or
farms. For example, frequently other family members fill
in for a sick person during the planting season in agri-
culture so that the same area of land is planted despite
the illness [63]. This does not, of course, mean that there
are no opportunity costs associated with the illness, but
that the measured production from the family enterprise
is not altered as much. In general, therefore, we expect
that the costs from studies with no controls to be over-
estimates of both direct and indirect costs.
The substantial variations in study designs and defini-
tions described earlier also make comparisons tricky and
meta-analysis infeasible. There is considerable hetero-
geneity in objectives and the methodologies used in the
papers. While we have more confidence in the studies
relying on randomized samples, we present more details
about each study in file 1: Table S1 to give readers fur-
ther information and to allow them to consider possible
generalizations of the results. Taking into consideration
the methodological issues highlighted here and in earlier
sections, we can still conclude that NCDs already im-
pose substantial financial costs on some of their sufferers
in lower-income countries. As a result, the cost of
obtaining treatment for NCDs is also becoming a cause
of impoverishment and financial catastrophe in these
countries. While this is not particularly surprising given
the growing burden of disease associated with these con-
ditions, it has not been documented before.
Again not surprisingly, complications related to the se-
verity of illness were found to increase the household fi-
nancial burden, both for the patient and for caregivers.
Health promotion, prevention and early treatment would
reduce some of these costs although each country would
need to choose the appropriate mix of prevention and
treatment according to their relative costs and impact.
We also found strong evidence that costs could be re-
duced by more rational use of medications for NCDs.
The costs of medication for all the different types of
NCDs considered here accounted for the highest pro-
portion of the direct costs; where addressed, originator
brand medicines were frequently used instead of avail-
able generics and costs were then substantially higher
than they needed to be. While many LMICs already have
strategies to promote the rational use of medicines, there
is still some way to go particularly in promoting the use
of lower cost generics.
The weakness or non-existence of mechanisms to pro-
tect households financially from the burden of NCDs is,
however, probably the most important finding in this
study. In the studies that considered insurance and pro-
vided information on reimbursement rates, NCD-related
treatment is generally uncommon and frequently pa-
tients and their relatives do not report that they claimed
any reimbursement from insurance or employers. Like-
wise, none of the studies we reviewed reported a system
of social security that provides compensation for loss of
income incurred by patients and their families because
of NCDs. Poor households are more likely to suffer dis-
proportionally from the financial effects of this lack of
social protection. To meet the costs, households re-
ported taking unsecure loans, using savings or selling
household assets, all of which can lead to longer-term
problems for the household. For example, the wider lit-
erature suggests that many of the loans taken by house-
holds for health expenses are at very high interest rates
that can take generations to repay [64]. This is part of a
bigger problem in LMICs, many of which rely exten-
sively on direct out-of-pocket payments to fund health
services. Recently, many have recognized the need to
modify the way they raise funds and more generally to
modify their health financing systems so as to improve
financial risk protection and ensure greater access to
needed health services [65]; it is important to note that
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it will be increasingly necessary to include NCDs in
whatever type of financial risk protection strategy is de-
veloped. This is particularly important for poor families
because NCDs no longer affect only the more affluent
people in society [1,8,13,66,67].
While we think that the financial costs reported in this
review will overestimate the costs of a typical patient
with NCDs, such that the numbers cannot be used to
extrapolate the costs of NCDs to a country, they high-
light the other consequences of the lack of financial risk
protection in LMICs. In the random sample studies,
many people with NCDs reported that they did not seek
care at all because of financial reasons (Additional file 2).
Many of their conditions are likely to become more severe
in the absence of treatment, leading to early death and
greater problems for caregivers and households. The ef-
fects of not seeking care for poorer households is of par-
ticular concern given that the ability to work is one of the
most important poverty escape routes [68-72]. Strategies
to improve financial risk protection will also lead to in-
creased financial access to health services while demand
side responses, such as cash transfers, can help reduce
some of the financial barriers to seeking care, such as
transport costs. Nevertheless, demand-side approaches in
LMICs are, to our knowledge, limited largely to maternal
and child health (and education) and some communicable
diseases [73-77].
Through this review, we are also able to identify areas
where further research is needed. Among the four major
NCDs, the financial costs from chronic respiratory dis-
eases are very poorly documented, although they cause
four times more deaths than for example diabetes, which
has been researched more [1,78]. According to the
WHO, almost 90% of COPD deaths occur in LMICs and
the highest prevalence of smoking – the primary cause
of COPD – among men is in these countries [1,78,79]. It
would therefore be interesting to have more assessments
of the financial costs of these diseases in future studies.
Additionally, while all studies reviewed here used cross-
sectional data, panel data will be very useful in assessing
the evolution of costs incurred by households because of
NCDs. The comparison of the relative importance of the
cost of NCDs with that of acute illnesses is also of a
great interest here, as according to the papers reviewed,
there is no clear trend. Indeed, some studies show that
NCDs are more costly for households, while others
observe the opposite. Sometimes in the same country,
different results are found depending on the area (urban
vs. rural), the type of health care (outpatient vs. in-
patient) and household socioeconomic status (poor vs.
better-off ) [17,21,38,39,44,55]. More studies – introdu-
cing for example a time dimension and a distinction be-
tween private and public providers – are therefore
needed to shed more light on this issue. It may also be
important to expand the geographical outlook in future
research to be more representative of a wider group of
developing countries. This is true even after accounting
for the influence of the languages used in this review. Of
the 49 studies found, most were from Asia, as compared
to only a handful from Latin America or Eastern Europe,
and 10 studies from Africa.
Conclusions
The literature on the social, financial and economic con-
sequences of NCDs in developing countries has not kept
pace with the epidemiological evidence. It has been
known for some time that the burden of disease associ-
ated with NCDs and injuries is already higher than that
associated with the health conditions included in the
Millennium Development Goals (HIV/AIDS, tubercu-
losis, malaria, and maternal, child and reproductive
health), even in developing countries. Moreover, it has
been well documented that the share of NCDs in the
overall disease burden will continue to increase globally.
Indeed, the UNs’ 2011 conference on NCDs stressed the
importance of these diseases as a development issue.
The literature we reviewed sheds some light on the fi-
nancial consequences of NCDs on households in LMICs.
Nonetheless, there are limitations to generalization of
these findings due to methodological challenges. Valid
estimates of the average costs of NCDs will require ran-
dom samples with controls to account for people who
have costly and less costly treatments, and what would
have happened in the absence of the diseases. Panel data
would be ideal although these studies are more expen-
sive than cross-sectional designs. However, importantly,
this review suggests that it is equally as important to
focus on people who could not seek care for NCDs due
to financial reasons. Little is known about the subse-
quent development of disease, impacts on these people’s
health and the financial, social and other consequences
associated with foregone treatment.
The push to develop health-financing systems that im-
prove financial risk protection and help achieve universal
health coverage in LMICs is promising. However, poli-
cymakers need to ensure that the health as well as the fi-
nancial burden from NCDs is adequately addressed in
future reforms, while at the same time improve access
and financial protection for all other health services
needed by the population.
Endnotes
aUS$ 995 or less, US$ 996 to US$ 3,945, and US$
3,946 to US$ 12,195, respectively.
bDefined as out-of-pocket expenses that accounted
for ≥30% of the total annual household income that
was reported at baseline.
Kankeu et al. Health Research Policy and Systems 2013, 11:31 Page 9 of 12
http://www.health-policy-systems.com/content/11/1/31
Additional files
Additional file 1: Table S1. Studies reviewed.
Additional file 2: Financial difficulties: a major cause for not
seeking care for NCDs.
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